Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alpha Cognition Inc (TSE:ACOG)
CNQX:ACOG
Holding TSE:ACOG?
Track your performance easily
ACOG Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$0.23 - C$0.99
Previous CloseC$0.51
Volume11.72K
Average Volume (3M)76.67K
Market Cap
C$76.94M
Enterprise ValueC$76.69M
Total Cash (Recent Filing)$1.40M
Total Debt (Recent Filing)$1.22M
Price to Earnings (P/E)―
Beta-0.52
Next Earnings
Nov 26, 2024EPS Estimate
-C$0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding150,855,536
10 Day Avg. Volume36,895
30 Day Avg. Volume76,669
Standard Deviation0.29
R-Squared0.21
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)-17.33
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-5.63
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Alpha Cognition Inc News
PremiumCompany Announcements
Alpha Cognition Secures Patent for Alzheimer’s Drug ZUNVEYLPremiumCompany Announcements
Alpha Cognition Inc. Adjusts Funding Strategy Amid Market Challenges
PremiumCompany Announcements
Alpha Cognition’s New Alzheimer’s Drug Wins FDA Approval
PremiumCompany Announcements
Alpha Cognition’s ZUNVEYL Wins FDA Approval for Alzheimer’sPremiumCompany Announcements
Alpha Cognition Enhances Investor Relations for Alzheimer’s DrugPremiumCompany Announcements
Alpha Cognition’s Resale Statement Goes Live
PremiumCompany Announcements
Alpha Cognition Advances Alzheimer’s Drug and Finances
PremiumCompany Announcements
Alpha Cognition Files SEC Resale RegistrationOptions Prices
Currently, No data available
---
Ownership Overview
14.96% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
85.04% Public Companies and
Individual Investors
ACOG FAQ
What was Alpha Cognition Inc’s price range in the past 12 months?
Alpha Cognition Inc lowest stock price was C$0.23 and its highest was C$0.99 in the past 12 months.
What is Alpha Cognition Inc’s market cap?
Currently, no data Available
When is Alpha Cognition Inc’s upcoming earnings report date?
Alpha Cognition Inc’s upcoming earnings report date is Nov 26, 2024 which is in 67 days.
How were Alpha Cognition Inc’s earnings last quarter?
Alpha Cognition Inc released its earnings results on Aug 12, 2024. The company reported -C$0.014 earnings per share for the quarter, beating the consensus estimate of -C$0.054 by C$0.04.
Is Alpha Cognition Inc overvalued?
According to Wall Street analysts Alpha Cognition Inc’s price is currently Overvalued.
Does Alpha Cognition Inc pay dividends?
Alpha Cognition Inc does not currently pay dividends.
What is Alpha Cognition Inc’s EPS estimate?
Alpha Cognition Inc’s EPS estimate is -C$0.05.
How many shares outstanding does Alpha Cognition Inc have?
Alpha Cognition Inc has 150,855,530 shares outstanding.
What happened to Alpha Cognition Inc’s price movement after its last earnings report?
Alpha Cognition Inc reported an EPS of -C$0.014 in its last earnings report, beating expectations of -C$0.054. Following the earnings report the stock price went up 1.538%.
Which hedge fund is a major shareholder of Alpha Cognition Inc?
Currently, no hedge funds are holding shares in TSE:ACOG
---
Alpha Cognition Inc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
52.23%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
12.39%
Trailing 12-Months
Company Description
Alpha Cognition Inc
Alpha Cognition Inc is a clinical-stage biopharmaceutical company dedicated to developing treatments for under-served neurodegenerative diseases such as Alzheimer's Disease and Amyotrophic Lateral Sclerosis. ALPHA-1062 is a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. It is being developed as a new acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type, with minimal gastrointestinal side effects and novel routes of administration.
---
Technical Analysis
---